The TSSP term loan facility will be available to the company in three tranches:
USD 200m will be immediately available upon the closing of the facility;
USD 50m will be available upon the designation of ANNOVERA as a new category of birth control by the US Food and Drug Administration on or prior to December 31, 2019; and
USD 50m will be available upon TherapeuticsMD achieving USD 11m in net revenues from IMVEXXY, BIJUVA and ANNOVERA for the fourth quarter of 2019
TherapeuticsMD anticipates that the TSSP term loan facility will close on or before May 10, 2019, subject to the satisfaction of certain customary conditions precedent.
Borrowings under the TSSP term loan facility will accrue interest at 3-month LIBOR plus 7.75%, subject to a LIBOR floor of 2.70%.
Interest on amounts borrowed under the facility will be payable quarterly.
The outstanding principal amount of the term loan facility will be payable in four equal quarterly installments beginning on June 30, 2023, with the term loan facility maturing on March 31, 2024.
TherapeuticsMD has notified its existing lender, MidCap Financial Trust, managed by Apollo Capital Management, L.P., that the company will be terminating its existing term loan credit and security agreement.
A portion of the initial tranche of the new TSSP facility will be used to repay amounts outstanding under the company's existing term loan credit and security agreement with MidCap Financial Trust.
TherapeuticsMD is focused on developing and commercialising novel products exclusively for women. These products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT